May 22, 2020
Takeda Pharmaceutical Co., Ltd
Otsuka Pharmaceutical Co., Ltd.
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin® Combination Tablets"
- Below is a summary English translation provided by Otsuka as a reference. The original and full press release in Japanese was issued by Takeda and Otsuka on May 22.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Takeda Pharmaceutical Co., Ltd. (Takeda) announce that "Cabpirin® Combination Tablets", a combination of vonoprazan fumarate ("vonoprazan") and low-dose aspirin has been launched.
Under the terms of a domestic co-promotion agreement formed in 2014, Takeda is to manufacture and promote Cabpirin, while promotional activities are to be conducted jointly by Otsuka and Takeda.
Takeda submitted to the Ministry of Health, Labor and Welfare an application for manufacturing and marketing approval of this combination tablet in June 2019 and obtained manufacturing and marketing approval on March 25, 2020. The Cabpirin combination tablet contains vonoprazan (also known as a P-CAB), a therapeutic agent for acid-related diseases that has a new mechanism of action, and low-dose aspirin. As such, it is believed that it could improve patient adherence.
Overview of Cabpirin® Combination Tablets
Risk reduction of formation of thrombosis/embolism due to the following disease or after operation (limited to the patients with history of gastric ulcer or duodenal ulcer)
|Dosage and administration||
For adults, an oral dose of one tablet (100 mg/10 mg of aspirin/vonoprazan) is usually administered once a day
Cabpirin® Combination Tablet 130.3 yen
Information in this news release was current as of the original release date.